GEN Exclusives

More »

GEN News Highlights

More »
May 21, 2008

Prana Obtains $6.74M Placement to Fund CNS Disease Drug Development

  • Prana Biotechnology raised over A$7 million, or approximately $6.74 million, through a private placement. The transaction included existing investors and represents a price of about $0.38 a share.

    Proceeds will advance development of the company's treatments for Alzheimer's and other neurodegenerative diseases such as Parkinson's and Huntington's diseases.

    “We are particularly gratified by the increased confidence shown by these investors who previously invested approximately six months ago at a value almost 50 percent below today's level,” states Geoffrey Kempler, chairman and CEO.

    “Since then we have achieved key milestones including a successful Phase IIa clinical trial of PBT2 and commencement of commercial discussions as well as the widening of our pipeline opportunities into different indications” Kempler continues. "We are progressing discussions with potential pharmaceutical partners and are confident that PBT2, our lead drug for Alzheimer's disease, offers a very attractive opportunity.”



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?